<unk>  is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.<unk>  binds to various aminophospholipids and is dependent on interaction with plasma protein beta2-glycoprotein 1 to mediate binding.
These target aminophospholipids, usually residing only on the inner leaflet of the plasma membrane of cells are purportedly only exposed in virally infected, damaged or malignant cells.
The drug’s binding to phospholipids, alerts the body’s immune system to attack the tumor endothelial cells, Thrombosing the tumors vascular network and/or attacking free floating virally infected and metastatic cells while potentially minimizing side effects in healthy tissues.
Bavituximab
Rituximab
Alemtuzumab
Volociximab
Ruxolitinib
Pertuzumab
Abiciximab
Matuzumab